共 18 条
- [11] The Novel Long Acting GLP-1/Glucagon Dual Agonist HM12525A Reduces Body Weight and Improves Glycermic Control in Rodent ModelsDIABETES, 2013, 62 : A268 - A268Jung, Sung YeobKim, Jin SunChoi, In YoungLee, Kyu HangLee, Young-MiKim, Young HoonKang, JahoonKwon, Se Chang
- [13] YH25724, a novel long-acting GLP-1/FGF21 dual agonist, induces body weight loss and improves glucose and lipid metabolism in obese diabetic monkeysHEPATOLOGY, 2017, 66 : 1054A - 1054AKim, Jun HwanHong, Han NaChoi, Hyun HoOh, Se-WoongJu, Mi KyeongLim, SeyoungHwang, Da-EunPark, Ju-YoungChoi, Byung HyunKim, Han-JooKim, Jong Gyun
- [14] A novel long-acting selective neuropeptide y2 receptor polyethylene glycol-conjugated peptide agonist reduces food intake and body weight and improves glucose metabolism in rodentsJOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 323 (02): : 692 - 700Ortiz, Astrid A.Milardo, Lucinda F.DeCarr, Lynn B.Buckholz, Thomas M.Mays, Michelle R.Claus, Thomas H.Livingston, James N.Mahle, Cathy D.Lumb, Kevin J.
- [15] Novel Dual Glucagon and Glucagon-Like Peptide-1 Receptor Agonist LY3305677 Improves Glucose Control, Reduces Body Weight, and Increases Energy Expenditure in MiceDIABETES, 2021, 70Chen, YanyunMezo, AdamCoskun, TamerSong, MinRoell, William C.Bokvist, Krister B.Moyers, Julie S.Thomas, Melissa K.Valenzuela, FranciscoQu, Hongchang
- [16] Tofogliflozin, a Novel and Selective SGLT2 Inhibitor Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Stable Metformin or Diet and Exercise AloneDIABETES, 2012, 61 : A22 - A22Kadowaki, TakashiIkeda, SachiyaTakano, YasukiCynshi, OsamuChrist, Andreas D.Boerlin, ViktorBeyer, UlrichBeck, Andreas
- [17] Canagliflozin, a Novel Inhibitor of Sodium Glucose Co-Transporter 2 (SGLT2) Improves Glycemic Control and Reduces Body Weight in Japanese Type 2 Diabetes Mellitus (T2DM)DIABETES, 2011, 60 : A274 - A274Inagaki, NobuyaKondo, KazuokiIwasaki, TakashiMaruyama, NobukoSusuta, YutakaSakai, MasakiKuki, Hideki
- [18] The Novel, Potent and Orally Available GPR119 Agonist AS1790091 Enhances Insulin Secretion and Insulin Promoter Activity, Preserves B-Cell Function, Improves Insulin Resistance, and Reduces Body Weight Gain in Type 2 Diabetic MiceDIABETES, 2011, 60 : A274 - A275Yoshida, ShigeruTanaka, HirotsuguOshima, HiroyukiYonetoku, YasuhiroOhishi, TakahideMatsui, TetsuoShibasaki, Masayuki